Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically or cytologically confirmed advanced solid tumor that is not curable by surgery or radiotherapy
• •* Sarcoma
• •* Melanoma
• •* Carcinoma of unknown primary
• •* Pancreatic cancer
• •* Lung cancer
• •* Ovarian cancer
• •* Breast cancer
• •* Bladder cancer
• •* Gastric cancer
• •* Esophageal cancer
• •* Prostate cancer
• •* Head and neck cancer
• •No hematopoietic or lymphoid tumors
• •Measurable or evaluable disease
• •PATIENT CHARACTERISTICS:
• •Age:
• •Over 18
• •Performance status:
• •Karnofsky 60-100%
• •ECOG 0-2
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •Absolute neutrophil count greater than 1,000/mm\^3
• •Platelet count greater than 100,000/mm\^3
• •Hepatic:
• •Bilirubin normal
• •AST and/or ALT no greater than 5 times upper limit of normal (ULN) if alkaline phosphatase no greater than ULN OR
• •Alkaline phosphatase no greater than 5 times ULN if AST and ALT no greater than ULN OR
• •AST and/or ALT no greater than 1.5 times ULN if alkaline phosphatase no greater than 2.5 times ULN
• •Renal:
• •Creatinine no greater than 2 times ULN OR
• •Creatinine clearance at least 50 mL/min
• •Cardiovascular:
• •No congestive heart failure
• •No unstable angina
• •Other:
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No uncontrolled infection
• •No known sensitivity to E. coli-derived products
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •At least 2 weeks since prior cytotoxic anti-tumor therapy (4 weeks for nitrosourea or mitomycin) and recovered
• •No prior docetaxel or gemcitabine
• •Endocrine therapy:
• •Not specified
• •Radiotherapy:
• •See Disease Characteristics
• •At least 2 weeks since prior radiotherapy and recovered
• •Surgery:
• •Not specified